Melio Bio
Leveraging human genetics for better cardiometabolic health
Melio Bio is focused on discovering and developing novel therapeutics against genetically validated targets critically implicated in cardiometabolic disease.
Next generation targets for metabolic health
At Melio Bio we are focused on delivering safer and better tolerated therapeutic options to improve patient responses for healthy metabolic fitness. With a focus on targets that are genetically validated, we aim to reduce fat mass whilst preserving healthy muscle mass, giving patients back a healthy and active lifestyle.
Identifying patient populations beyond obesity
We go beyond obesity. Comorbidities that are closely linked to obesity include Type 2 diabetes, liver disease (MASLD) and pulmonary hypertension. We leverage patient data to understand and identify risk factors that can be used to predict onset of comorbidities, aiming to stop them in their tracks.
